Korean J Med.  2017 Feb;92(1):62-65. 10.3904/kjm.2017.92.1.62.

Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure

Affiliations
  • 1Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. parkjrang@gmail.com

Abstract

Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.

Keyword

Tolvaptan; Osmotic demyelination syndrome; Heart failure

MeSH Terms

Aged
Atrial Fibrillation
Demyelinating Diseases*
Female
Heart Failure*
Heart*
Humans
Hyponatremia
Prognosis
Receptors, Vasopressin
Receptors, Vasopressin
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr